Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors.

Saved in:
Bibliographic Details
Title: Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors.
Authors: Liu R; Phase I Clinical Research Center, Fudan University Cancer Hospital, Shanghai, 200000, China., Jing H; Department of Pulmonary and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, 210000, China., Chen Y; Phase I Clinical Research Center, Fudan University Cancer Hospital, Shanghai, 200000, China., Gao S; Phase I Clinical Research Center, Fudan University Cancer Hospital, Shanghai, 200000, China., Zhang J; Department of Pulmonary and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, 210000, China., Cao X; Department of Pulmonary and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, 210000, China., Li K; Department of Pulmonary and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, 210000, China., Liu Y; Department of Pulmonary and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, 210000, China., Meng M; Department of Pulmonary and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, 210000, China., Chen C; Shanghai Henlius Biotech, Inc., Shanghai, China., Sun C; Shanghai Henlius Biotech, Inc., Shanghai, China., Yu H; Shanghai Henlius Biotech, Inc., Shanghai, China., Wang Q; Shanghai Henlius Biotech, Inc., Shanghai, China., Li J; Shanghai Henlius Biotech, Inc., Shanghai, China., Wu Y; Department of Pulmonary and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, 210000, China. wymin666@126.com., Zhang J; Phase I Clinical Research Center, Fudan University Cancer Hospital, Shanghai, 200000, China. syner2000@163.com.
Source: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2026 Mar; Vol. 40 (2), pp. 335-348. Date of Electronic Publication: 2026 Jan 15.
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9705305 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-190X (Electronic) Linking ISSN: 11738804 NLM ISO Abbreviation: BioDrugs Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1179-190X
DOI:10.1007/s40259-025-00751-z